Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBIT: 2023-2024

Historic EBIT for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$17.0 million.

  • Contineum Therapeutics' EBIT fell 76.18% to -$17.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$50.9 million, marking a year-over-year decrease of 416.57%. This contributed to the annual value of -$50.9 million for FY2024, which is 416.56% down from last year.
  • Latest data reveals that Contineum Therapeutics reported EBIT of -$17.0 million as of Q4 2024, which was down 31.39% from -$13.0 million recorded in Q3 2024.
  • Over the past 5 years, Contineum Therapeutics' EBIT peaked at $38.9 million during Q2 2023, and registered a low of -$17.0 million during Q4 2024.
  • Over the past 2 years, Contineum Therapeutics' median EBIT value was -$9.8 million (recorded in 2023), while the average stood at -$4.4 million.
  • Data for Contineum Therapeutics' EBIT shows a maximum YoY plummeted of 128.11% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Contineum Therapeutics' EBIT stood at -$9.7 million in 2023, then plummeted by 76.18% to -$17.0 million in 2024.
  • Its EBIT stands at -$17.0 million for Q4 2024, versus -$13.0 million for Q3 2024 and -$10.9 million for Q2 2024.